Shares

37 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$13.58 - $17.36 $369,647 - $472,539
27,220 New
27,220 $428,000
Q2 2023

Apr 29, 2024

BUY
$13.28 - $15.96 $361,481 - $434,431
27,220 New
27,220 $383,000
Q1 2023

May 09, 2024

BUY
$14.26 - $22.1 $388,157 - $601,562
27,220 New
27,220 $421 Million
Q1 2023

May 15, 2023

BUY
$14.26 - $22.1 $53,503 - $82,919
3,752 Added 15.99%
27,220 $420,000
Q4 2022

Jun 14, 2023

SELL
$14.85 - $19.04 $55,717 - $71,438
-3,752 Reduced 13.78%
23,468 $384,000
Q3 2022

Jun 14, 2023

SELL
$12.38 - $20.23 $46,449 - $75,902
-3,752 Reduced 13.78%
23,468 $434,000
Q2 2022

Jun 20, 2023

SELL
$9.11 - $13.98 $34,180 - $52,452
-3,752 Reduced 13.78%
23,468 $308,000
Q1 2022

May 10, 2024

BUY
$6.87 - $11.11 $161,225 - $260,729
23,468 New
23,468 $217,000
Q1 2022

Jun 20, 2023

SELL
$6.87 - $11.11 $25,776 - $41,684
-3,752 Reduced 13.78%
23,468 $217,000
Q1 2022

Mar 22, 2023

BUY
$6.87 - $11.11 $57,213 - $92,524
8,328 Added 55.01%
23,468 $217,000
Q1 2022

May 12, 2022

BUY
$6.87 - $11.11 $57,213 - $92,524
8,328 Added 55.01%
23,468 $218,000
Q4 2021

Jun 21, 2023

SELL
$7.7 - $37.13 $93,016 - $448,530
-12,080 Reduced 44.38%
15,140 $147,000
Q3 2021

Jun 21, 2023

SELL
$26.46 - $37.15 $319,636 - $448,772
-12,080 Reduced 44.38%
15,140 $514,000
Q2 2021

Jun 21, 2023

SELL
$32.73 - $47.95 $395,378 - $579,236
-12,080 Reduced 44.38%
15,140 $554,000
Q1 2021

May 17, 2024

SELL
$40.39 - $56.73 $487,911 - $685,298
-12,080 Reduced 44.38%
15,140 $678,000
Q1 2021

Jun 26, 2023

SELL
$40.39 - $56.73 $487,911 - $685,298
-12,080 Reduced 44.38%
15,140 $679 Million
Q4 2020

May 24, 2024

SELL
$51.77 - $66.18 $75,480 - $96,490
-1,458 Reduced 8.78%
15,140 $864,000
Q4 2020

Jun 22, 2023

SELL
$51.77 - $66.18 $625,381 - $799,454
-12,080 Reduced 44.38%
15,140 $864,000
Q4 2020

Mar 22, 2023

SELL
$51.77 - $66.18 $75,480 - $96,490
-1,458 Reduced 8.78%
15,140 $864,000
Q4 2020

Feb 16, 2021

SELL
$51.77 - $66.18 $75,480 - $96,490
-1,458 Reduced 8.78%
15,140 $864,000
Q3 2020

Jun 26, 2023

SELL
$43.8 - $58.16 $465,243 - $617,775
-10,622 Reduced 39.02%
16,598 $851,000
Q2 2020

May 24, 2024

SELL
$37.05 - $65.03 $393,545 - $690,748
-10,622 Reduced 39.02%
16,598 $991 Million
Q2 2020

Jun 26, 2023

SELL
$37.05 - $65.03 $393,545 - $690,748
-10,622 Reduced 39.02%
16,598 $991,000
Q2 2020

Mar 22, 2023

BUY
$37.05 - $65.03 $291,805 - $512,176
7,876 Added 90.3%
16,598 $991,000
Q2 2020

Aug 14, 2020

BUY
$37.05 - $65.03 $291,805 - $512,176
7,876 Added 90.3%
16,598 $991,000
Q1 2020

Jul 12, 2023

SELL
$33.63 - $69.4 $622,087 - $1.28 Million
-18,498 Reduced 67.96%
8,722 $359,000
Q4 2019

Jul 12, 2023

SELL
$31.7 - $69.93 $586,386 - $1.29 Million
-18,498 Reduced 67.96%
8,722 $542,000
Q4 2019

Mar 22, 2023

BUY
$31.7 - $69.93 $36,740 - $81,048
1,159 Added 15.32%
8,722 $542,000
Q4 2019

Feb 14, 2020

BUY
$31.7 - $69.93 $36,740 - $81,048
1,159 Added 15.32%
8,722 $543,000
Q3 2019

Jul 12, 2023

SELL
$19.95 - $38.85 $392,157 - $763,674
-19,657 Reduced 72.22%
7,563 $256,000
Q3 2019

Mar 22, 2023

BUY
$19.95 - $38.85 $29,665 - $57,769
1,487 Added 24.47%
7,563 $256,000
Q3 2019

Nov 14, 2019

BUY
$19.95 - $38.85 $150,881 - $293,822
7,563 New
7,563 $257,000
Q2 2019

Jul 12, 2023

SELL
$21.05 - $26.21 $413,779 - $515,209
-19,657 Reduced 72.22%
7,563 $171 Million
Q4 2018

Feb 14, 2019

SELL
$19.08 - $36.14 $115,930 - $219,586
-6,076 Closed
0 $0
Q3 2018

Jul 13, 2023

SELL
$33.57 - $42.1 $782,315 - $981,098
-23,304 Reduced 85.61%
3,916 $151,000
Q3 2018

Mar 22, 2023

SELL
$33.57 - $42.1 $583,849 - $732,203
-17,392 Reduced 74.11%
6,076 $235,000
Q3 2018

Nov 14, 2018

BUY
$33.57 - $42.1 $203,971 - $255,799
6,076 New
6,076 $235,000

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.